Evidence map›Paper›PMID 40470838›Full record

ArticleParasite immunology2025

Analysis of miR-10a and IFNG Expression Before and After Treatment for Chronic Schistosomiasis mansoni.

Débora Nascimento da Nóbrega, Ana Virgínia Matos Sá Barreto, Roberta Dos Santos Souza, Kleyton Palmeira do Ó, Raul Emídio de Lima, Ana Lúcia Coutinho Domingues, Edmundo Pessoa Lopes, Clarice Neuenschwander Lins de Morais, Elainne Christine de Souza Gomes, Luydson Richardson Silva Vasconcelos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parasite immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Débora Nascimento da NóbregaInstituto Aggeu Magalhães (IAM/Fiocruz), Recife, Pernambuco, Brazil.ORCID 0000-0002-1181-5542
Ana Virgínia Matos Sá BarretoCentro Universitário Maurício de Nassau (UNINASSAU), Recife, Pernambuco, Brazil.
Roberta Dos Santos SouzaInstituto Aggeu Magalhães (IAM/Fiocruz), Recife, Pernambuco, Brazil.
Kleyton Palmeira do ÓInstituto Aggeu Magalhães (IAM/Fiocruz), Recife, Pernambuco, Brazil.
Raul Emídio de LimaInstituto Aggeu Magalhães (IAM/Fiocruz), Recife, Pernambuco, Brazil.
Ana Lúcia Coutinho DominguesUniversidade Federal de Pernambuco, Hospital das Clínicas, Recife, Pernambuco, Brazil.
Edmundo Pessoa LopesUniversidade Federal de Pernambuco, Hospital das Clínicas, Recife, Pernambuco, Brazil.
Clarice Neuenschwander Lins de MoraisInstituto Aggeu Magalhães (IAM/Fiocruz), Recife, Pernambuco, Brazil.
Elainne Christine de Souza GomesInstituto Aggeu Magalhães (IAM/Fiocruz), Recife, Pernambuco, Brazil.
Luydson Richardson Silva VasconcelosInstituto Aggeu Magalhães (IAM/Fiocruz), Recife, Pernambuco, Brazil.

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorFundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco IBPG-1686-2.02/19
6 · The paper itself

Abstract

Mir-10a acts in signalling pathways regulating transcription, translation, and RNA-mediated gene silencing, while IFNG acts in the T-cell receptor signalling pathway. Thus, both can be considered potential targets for understanding regulatory processes in chronic inflammation in patients with schistosomiasis. Populations in endemic areas receive mass and indiscriminate praziquantel treatment, and yet patients often have a history of multiple infections. To investigate the regulatory and prognostic capacity of miR-10 and IFNG in patient immunity, we evaluated the expression of miR-10a and IFNG as biomarkers of inflammation and their correlation with praziquantel treatment. miR-10a did not present evidence as a biomarker of inflammation in the therapeutic follow-up in schistosomiasis. However, the levels of IFNG expression were significantly higher before treatment.

Indexed as

AnthelminticsInterferon-gammaMicroRNAsPraziquantelSchistosomiasis mansoniAdultAnimalsBiomarkersChronic DiseaseFemaleHumansMaleMiddle AgedYoung AdultAnthelminticsBiomarkersIFNG protein, humanInterferon-gammaMicroRNAsMIRN10 microRNA, humanPraziquantelgene expression regulationinterferon‐gammamicroRNApraziquantelschistosomiasis

Identifiers

PMID40470838
PMCPMC12139366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.